07 Oct
T-Cell Therapy Could Be Key to Battling Cancer T-Cell Therapy Could Be Key to Battling Cancer

T-Cell Therapy Could Be Key to Battling Cancer

Written by 

In late August, the FDA approved tisagenlecleucel for treatment in relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The approval was specific to children and young adults, but it’s considered an important first step in the eventual use of this type of therapy in other cancer incidents.

Also known as CAR T-Cell therapy, this treatment involves removing T cells from a patient and genetically modifying them so that when re-implanted, they attack B cells. The treatment attacks all B cells, not just the cancerous ones, but it is an improvement over traditional therapy for this type of leukemia. Currently, patients with B-cell precursor acute lymphoblastic leukemia undergo some combination of radiation, chemotherapy, targeted therapy, or a stem cell transplant, with long-term success rates extremely poor.

One negative to CAR T-Cell therapy is affordability. Just one infusion will cost a patient $475,000, which doesn’t include the price of pre-infusion treatments and hospitalization. But experts see the approval of this therapy as only the beginning for this type of treatment. Novartis states that this cost is lower than the cost of a stem cell transplant, which was the only potential cure for patients with this type of leukemia in previous years.

Rate this item
(0 votes)
Read 2119 times Last modified on Wednesday, 27 September 2017 07:18
Stephanie Faris

Stephanie is a freelance writer and novelist whose work has appeared on,, the Intuit Small Business Blog, and many others. She is the Simon & Schuster author of 8 children's books, including the Piper Morgan chapter book series, 25 Roses, and 30 Days of No Gossip.

Login to post comments
Home Our Blog T-Cell Therapy Could Be Key to Battling Cancer

Newsletter Signup

Live support

Available Monday - Friday, 9 AM - 5 PM EST

Connect with us

Netributor Main Offices